The FDA on January 12, 2018 granted approval to GILOTRIF® for a broadened indication in first-line treatment of patients with metastatic Non-Small Cell Lung Cancer (NSCLC) whose tumors have non-resistant Epidermal Growth Factor Receptor (EGFR) mutations, as detected by an FDA-approved test. GILOTRIF® is a product of Boehringer Ingelheim Pharmaceutical, Inc.
Bottom Ad
Advertisement
Subscribe
